Podcast Episodes

Back to Search
Ep. 90 – Inside Biopharma Dealmaking: ProFound CEO John Lepore on Knowing What Partners Want
Ep. 90 – Inside Biopharma Dealmaking: ProFound CEO John Lepore on Knowing What Partners Want

Season 4 Episode 90

In an environment where everybody hurts, it helps for biotech CEOs to understand the pressures driving pharmas, investors and other key players if th…

1 year, 1 month ago

Short Long
View Episode
Ep. 89 - Delivering on the biosimilars promise, a conversation with Gillian Woollett
Ep. 89 - Delivering on the biosimilars promise, a conversation with Gillian Woollett

Season 4 Episode 89

Gillian Woollett, head of regulatory strategy and policy at Samsung Bioepis, discusses how FDA can deliver on its promise to “massively streamline” t…

1 year, 1 month ago

Short Long
View Episode
Ep. 88 – From Satiety to Muscle: Zealand CEO Steensberg on Amylin’s Edge in Obesity
Ep. 88 – From Satiety to Muscle: Zealand CEO Steensberg on Amylin’s Edge in Obesity

Season 4 Episode 88

Mounting clinical evidence suggests amylin agonists could supplant GLP-1 molecules as the foundational backbone of future obesity therapy, says Zeala…

1 year, 2 months ago

Short Long
View Episode
Ep. 87 – Korea’s Biotech Playbook: Orum CEO SJ Lee on Going Global and Creating Novel Therapies
Ep. 87 – Korea’s Biotech Playbook: Orum CEO SJ Lee on Going Global and Creating Novel Therapies

Season 4 Episode 87

Globalizing quickly and gaining a first-mover advantage are the winning strategies for South Korean biotechs as they look to compete on the world sta…

1 year, 2 months ago

Short Long
View Episode
Ep. 86 – Macrophages, ASCO & Clever-1: Faron CEO Juho Jalkanen on Bexmarilimab’s Promise
Ep. 86 – Macrophages, ASCO & Clever-1: Faron CEO Juho Jalkanen on Bexmarilimab’s Promise

Season 4 Episode 86

The macrophage field has seen its share of setbacks, but Faron believes bexmarilimab, its humanized mAb that binds to immune checkpoint target Clever…

1 year, 3 months ago

Short Long
View Episode
Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets

Season 4 Episode 85

Notwithstanding the bad start that the Trump administration got off to on FDA, Tim Opler is optimistic that the agency will serve drug developers wel…

1 year, 3 months ago

Short Long
View Episode
Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva
Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva

Season 4 Episode 84

As CEO of a vintage 2021 biotech, Jorge Santos Da Silva has had his leadership mettle tested by a pandemic, rising interest rates, a bear market, and…

1 year, 3 months ago

Short Long
View Episode
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity

Season 4 Episode 83

Europe did not ask for this opportunity, says VIB’s Jérôme van Biervliet, but with FDA and the U.S. research funding situation headed into uncertain …

1 year, 4 months ago

Short Long
View Episode
Ep. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes
Ep. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes

Season 4 Episode 82

The U.S. will cede its preeminence in biotechnology to China within three years unless the government acts urgently, an independent commission charte…

1 year, 4 months ago

Short Long
View Episode
Ep. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies
Ep. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies

Season 4 Episode 81

On the latest episode of The BioCentury Show, Editor in Chief Simone Fishburn speaks with Bahija Jallal, CEO of Immunocore and the former president o…

1 year, 5 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us